Off Patent
July 2026

Akten

lidocaine hydrochloride

Thea Pharma Inc

Gel (ophthalmic) · NDA 022221

Last listed protection ended
July 24, 2026

The FDA listed 1 patent for Akten, and this is the day the last one ended. It is not the date a generic goes on sale.

Patents and exclusivities

  1. Ended
    Patent 8,759,401
    Claims the drug product and a use (U-1523)